These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 2136919

  • 21. Effects of pertussis toxin on D2-dopamine receptor in rat striatum: evidence for coupling of Ni regulatory protein with D2-receptor.
    Fujita N, Nakahiro M, Fukuchi I, Saito K, Yoshida H.
    Brain Res; 1985 May 06; 333(2):231-6. PubMed ID: 3158374
    [Abstract] [Full Text] [Related]

  • 22. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding.
    Sibley DR, Weinberger S, Segal DS, Creese I.
    Experientia; 1982 Oct 15; 38(10):1224-5. PubMed ID: 6890464
    [No Abstract] [Full Text] [Related]

  • 23. Correlated asymmetries in striatal D1 and D2 binding: relationship to apomorphine-induced rotation.
    Glick SD, Lyon RA, Hinds PA, Sowek C, Titeler M.
    Brain Res; 1988 Jul 05; 455(1):43-8. PubMed ID: 2970881
    [Abstract] [Full Text] [Related]

  • 24. Cyclo (Leu-Gly) attenuates the striatal dopaminergic supersensitivity induced by chronic morphine.
    Lee JM, DeLeon-Jones F, Fields JZ, Ritzmann RF.
    Alcohol Drug Res; 1987 Jul 05; 7(1):1-10. PubMed ID: 2431697
    [Abstract] [Full Text] [Related]

  • 25. Enhanced stereotypic behavior by chronic treatment with bromocriptine accompanies increase of D-1 receptor binding.
    Le WD, Zhou XD, Jin GZ.
    Life Sci; 1988 Jul 05; 42(19):1841-5. PubMed ID: 2966885
    [Abstract] [Full Text] [Related]

  • 26. Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands.
    Claudi F, Giorgioni G, Di Stefano A, Abbracchio MP, Paoletti AM, Balduini W.
    J Med Chem; 1992 Nov 13; 35(23):4408-14. PubMed ID: 1360027
    [Abstract] [Full Text] [Related]

  • 27. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y, Fage D, Zivkovic B, Scatton B.
    J Pharmacol Exp Ther; 1985 Feb 13; 232(2):519-25. PubMed ID: 2857197
    [Abstract] [Full Text] [Related]

  • 28. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S, Rupniak NM, Hall MD, Jenner P, Marsden CD.
    Biochem Pharmacol; 1983 Oct 01; 32(19):2921-7. PubMed ID: 6138043
    [Abstract] [Full Text] [Related]

  • 29. Dissociation between behavioral effects of (-)-N-(2-chloroethyl)-norapomorphine and D2 dopamine receptor-like activity.
    Helmeste DM.
    Eur J Pharmacol; 1983 Nov 25; 95(3-4):277-81. PubMed ID: 6317413
    [Abstract] [Full Text] [Related]

  • 30. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
    Knoerzer TA, Watts VJ, Nichols DE, Mailman RB.
    J Med Chem; 1995 Aug 04; 38(16):3062-70. PubMed ID: 7636869
    [Abstract] [Full Text] [Related]

  • 31. Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides.
    de Paulis T, Kumar Y, Johansson L, Rämsby S, Hall H, Sällemark M, Angeby-Möller K, Ogren SO.
    J Med Chem; 1986 Jan 04; 29(1):61-9. PubMed ID: 3941414
    [Abstract] [Full Text] [Related]

  • 32. Behavioral sensitization following subchronic apomorphine treatment--possible neurochemical basis.
    Vaughn DM, Severson JA, Woodward JJ, Randall PK, Riffee WH, Leslie SW, Wilcox RE.
    Brain Res; 1990 Aug 27; 526(1):37-44. PubMed ID: 2150341
    [Abstract] [Full Text] [Related]

  • 33. [3H]Fluphenazine binding to brain membranes: simultaneous measurement of D-1 and D-2 receptor sites.
    Morgan DG, Finch CE.
    J Neurochem; 1986 May 27; 46(5):1623-31. PubMed ID: 2937884
    [Abstract] [Full Text] [Related]

  • 34. Phosphorylation by cyclic AMP-dependent protein kinase modulates agonist binding to the D2 dopamine receptor.
    Elazar Z, Fuchs S.
    J Neurochem; 1991 Jan 27; 56(1):75-80. PubMed ID: 1846178
    [Abstract] [Full Text] [Related]

  • 35. Single apomorphine pretreatment results in a rapid decline in high-affinity dopamine binding to the striatal dopamine D-2 receptor.
    Severson JA, Randall PK, Wilcox RE.
    Eur J Pharmacol; 1990 Apr 25; 188(4-5):283-6. PubMed ID: 2114303
    [Abstract] [Full Text] [Related]

  • 36. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes.
    Von Euler G, Fuxe K.
    Acta Physiol Scand; 1987 Dec 25; 131(4):625-6. PubMed ID: 3442244
    [No Abstract] [Full Text] [Related]

  • 37. N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists.
    Herm L, Berényi S, Vonk A, Rinken A, Sipos A.
    Bioorg Med Chem; 2009 Jul 01; 17(13):4756-62. PubMed ID: 19454369
    [Abstract] [Full Text] [Related]

  • 38. 2-Haloaporphines as potent dopamine agonists.
    Ramsby S, Neumeyer JL, Grigoriadis D, Seeman P.
    J Med Chem; 1989 Jun 01; 32(6):1198-201. PubMed ID: 2524592
    [Abstract] [Full Text] [Related]

  • 39. In situ molecular size of agonist dopamine D-2 binding sites in rat striatum.
    Gredal O, Nielsen M.
    J Neurochem; 1987 Feb 01; 48(2):364-9. PubMed ID: 3794711
    [Abstract] [Full Text] [Related]

  • 40. Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine.
    Neumeyer JL, Arana GW, Ram VJ, Kula NS, Baldessarini RJ.
    J Med Chem; 1982 Aug 01; 25(8):990-2. PubMed ID: 7120288
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.